Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.44 |
| ▸ | CNR2 | P34972 | 17/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.39 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1235869 | 0.89 | CNR2 (0.44) | CNR1CNR2LTB4RLTB4R2 | |
| SCHEMBL1238204 | 0.86 | CNR1 (0.39) | CNR1CNR2 | |
| SCHEMBL1264702 | 0.84 | CNR2 (0.45) | CNR1CNR2 | |
| SCHEMBL1235880 | 0.83 | CNR2 (0.37) | CNR1CNR2 | |
| SCHEMBL1192994 | 0.82 | CNR1 (0.39) | CNR1CNR2LTB4RLTB4R2 | |
| SCHEMBL1235919 | 0.79 | CNR2 (0.51) | CNR1CNR2GPR18GPR55 | |
| SCHEMBL1265703 | 0.77 | CNR1 (0.39) | CNR1CNR2 | |
| SCHEMBL1491145 | 0.76 | CNR2 (0.46) | CNR1CNR2LTB4RLTB4R2GPR18 | |
| SCHEMBL1192791 | 0.74 | LTB4R (0.41) | CNR1CNR2LTB4RLTB4R2 | |
| SCHEMBL4884009 | 0.71 | CNR1 (0.76) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431595-B2 | Furanopyridine cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-04-30 | — | — | US | claimed |
| US-20110046176-A1 | FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-02-24 | — | — | US | claimed |
| US-8431595-B2 | Furanopyridine cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431595-B2 | Furanopyridine cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431595-B2 | Furanopyridine cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110046176-A1 | FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-02-24 | — | — | US | disclosed |
| US-20110046176-A1 | FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-02-24 | — | — | US | disclosed |
| US-20110046176-A1 | FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-02-24 | — | — | US | disclosed |
| WO-2011022692-A2 | FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046176-A1 | FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885LTB4R 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.